New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
06:33 EDTONCYOncolytics Biotech announce positive top line Reolysindata for Phase III study
Oncolytics Biotech announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naive head and neck cancers. The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans, typically performed at six weeks post-first treatment, of all patients enrolled in the study. The analysis was designed to assess early differences in response between loco-regional tumours and metastatic tumours, as classified and observed by the investigators. This is the first, and to this point only, endpoint to be un-blinded for this study.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
06:42 EDTONCYOncolytics announces Phase 1 study in pediatric patients with brain tumors
Subscribe for More Information
06:33 EDTONCYOncolytics says application of Reolysin with GM-CSF is now active
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use